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Abstract
Background An imbalance between proteolytic enzymes
and their inhibitors is thought to be involved in the path-
ogenesis of chronic obstructive pulmonary disease. Matrix
metalloproteinase-1, also known as interstitial collagenase,
has been implicated as a potentially important proteinase in
the genesis of chronic obstructive pulmonary disease and,
more specifically, emphysema.
Methods We performed quantitative immunohistochemi-
cal assessment of matrix metalloproteinase-1 expression in
the resected lung of 20 smokers/ex-smokers who had vary-
ing severity of airflow obstruction and emphysema and
compared this with the lungs of 5 nonsmokers. Emphysema
was measured using a morphometric measure of the lungs’
surface area/volume ratio and with qualitative and quanti-
tative computed tomography (CT) measures of emphysema.
Results There were significantly more matrix metallo-
proteinase-1-expressing alveolar macrophages and type II
pneumocytes as well as a greater percentage of small air-
ways that stained positively for matrix metalloproteinase-1
in the lungs of smokers than in those of nonsmokers
(p \ 0.0001, p \ 0.0001, and p = 0.0003, respectively).
The extent of staining of type II pneumocytes and airways
for matrix metalloproteinase-1 was significantly related to
the extent of smoking (p = 0.012 and p = 0.013, respec-
tively). In addition, the extent of matrix metalloproteinase-
1 staining of alveolar macrophages was related to the lung
surface area/volume ratio and to qualitative estimates of
emphysema on CT.
Conclusion These findings suggest that cigarette smoking
increases expression of matrix metalloproteinase-1 in
alveolar macrophages as well as in alveolar and small
airway epithelial cells. Smokers who develop emphysema
have increased alveolar macrophage expression of matrix
metalloproteinase-1.
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Cigarette smoke is the primary risk factor for chronic
obstructive pulmonary disease (COPD), a disease state
characterized by airflow limitation that is not fully
reversible [1]. Not everyone who smokes develops COPD,
and when it does occur, the pathological changes vary
between patients and at different stages of the disease. The
variable susceptibility and phenotypes suggest that there is
a genetic component to the disease. Pathologic changes
characteristic of COPD are found in the large airways,
small airways (\2 mm), and alveoli. Chronic inflammation
leads to fixed narrowing and obliteration of small airways
and alveolar wall destruction; both changes result in air-
flow limitation.
More than 30 years ago, Hogg et al. [2] proposed that
COPD is primarily a disease of the small airways based on
the observation that the peripheral airways are the major
site of increased resistance to airflow. Changes that con-
tribute to the narrowing of the small airways include loss of
alveolar and bronchiolar attachments, goblet-cell metapla-
sia, edema, inflammatory cellular infiltration, reduced
surfactant, smooth muscle hyperplasia, and fibrosis [3].
The narrowing and obliteration of the small airways cou-
pled with the loss of lung elastic recoil caused by paren-
chymal destruction leads to expiratory airflow limitation.
The destruction of the lung parenchyma, which causes the
lesions of emphysema, is believed to be due to an imbal-
ance between the proteolytic and antiproteolytic processes
in the lung. A number of proteolytic enzymes have been
implicated in the disease process, including matrix
metalloproteinases (MMPs), a family of zinc-dependent
proteinases with the capacity to degrade both elastin and
collagen.
MMP-1 is one of the most abundant proteases in the
MMP family and is capable of degrading type I, II, and III
collagens. Type I and III collagens are the most abundant
proteins within the lung. The finding that MMP-1 trans-
genic mice overexpressing MMP-1 develop emphysema-
tous changes in their lungs showed a direct contribution of
MMPs to this proteolytic destruction [4, 5]. Further evi-
dence from animal and human studies supports a role for
collagenolytic enzymes and, in particular, MMP-1 in the
pathogenesis of emphysema [6–9]. Genetic studies have
also shown that MMP-1 polymorphisms are associated
with COPD phenotypes [10, 11]. Alveolar macrophages,
type II pneumocytes, and airway epithelial cells are known
to express MMP-1 [7, 9]. In vitro studies have shown that
cigarette smoke directly targets the MMP-1 promoter in
human small-airway epithelial cells [12] and that this
increase in expression is regulated via the extracellular
regulated kinase/mitogen-activated protein kinase pathway
[13]. Individual sensitivity to upregulation of expression of
MMP-1 in response to cigarette smoke could contribute to
individual susceptibility for COPD among smokers. Imai
et al. [7] have previously identified alveolar macrophages
and type II pneumocytes as two important cell types in the
lung responsible for MMP-1 expression. Unfortunately, the
study was limited by the small number of subjects (only
two) who were long-term smokers but had normal lung
tissue and therefore they were not able to compare the
expression of MMP-1 in smokers with and without
emphysema.
In the present study we quantified MMP-1 expression
within the lung by immunohistochemistry and related
MMP-1 expression to histological and computed tomog-
raphy (CT) measures of emphysema in order to better
evaluate the pathogenic role of this enzyme.
Methods
Human lung specimens were obtained from 25 patients.
Twenty lobes or lungs were obtained from smokers at the
time of surgical resection for small (\3 cm diameter),
stage I or II, peripheral tumors at the Vancouver General
Hospital in Vancouver. Study participants who quit
smoking 6 months or more prior to surgery were consid-
ered former smokers (n = 12); the remaining subjects in
the smoking group were classified as current smokers
(n = 8). The lungs or lobes of five never-smokers were
obtained as controls from individuals who had surgical
resection for various indications at St. Paul’s Hospital in
Vancouver. Within the week prior to surgery the patients
completed a questionnaire regarding smoking and respira-
tory symptoms and had measurements of subdivisions of
lung volume, spirometry, and single-breath diffusing
capacity as previously described and conforming to ATS
standards [14]. Subjects provided informed consent. The
study was approved by the University of British Columbia/
Providence Health Care and Vancouver General Hospital
Research Ethics Boards. Statistical analysis was performed
using R 2.4.0 (Auckland, NZ). As a quantitative estimate of
lifetime exposure to cigarette smoke, we used pack-years
as ascertained in the preoperative interview. Unpaired t-
tests were used to compare anthropometric, physiological,
and morphological data of never-smokers with those of
smokers and to make comparisons between former smokers
and current smokers. Simple linear regression was used to
estimate the associations between MMP-1 staining (alve-
olar macrophages, type II pneumocytes, and airways) and
morphometric estimates of emphysema (Sa/V), as well as
the qualitative and quantitative CT values. P values less
than 0.05 were considered statistically significant. Details
of the immunohistochemistry, image analysis, and CT
analysis can be found in the Online Resource.




The demographics, smoking history, and pulmonary func-
tion of the subjects are presented in Table 1. In our sample,
the never-smokers were significantly younger than the
smokers (p = 0.027). Pulmonary function tests showed
that the smokers had a reduced forced expiratory volume in
1 second (FEV1) compared with the never-smokers
(p = 0.002) and a lower diffusing capacity for carbon
monoxide (p = 0.033).
Cellular Localization of MMP-1
Immunohistochemistry was undertaken to identify the cell
type(s) responsible for MMP-1 expression within the lung.
MMP-1 was immunolocalized to alveolar macrophages
(Fig. 1a), type II pneumocytes (Fig. 1a, b), and airways
(Fig. 1d). Negative controls are shown in Fig. 1c, e.
Comparison of MMP-1-Positive Cells
in the Never-Smoker and Smoker Groups
Table 2 shows the amount of MMP-1-positive cells in the
never-smoker and smoker groups. Smokers had signifi-
cantly more MMP-1-positive stained alveolar macrophages
(p \ 0.0001), type II pneumocytes (p \ 0.0001), and air-
ways (p \ 0.0003). Type II pneumocytes did not stain
positively for MMP-1 in the lungs of never-smokers,
staining was weakly positive in alveolar macrophages, and
only one nonsmoker had any positive airway staining.
To determine if the amount of MMP-1 staining and
qualitative CT score were affected by current smoking
status, we divided the smoking group into former smokers
and current smokers. Table 3 shows that there were no
significant differences between the two subgroups in terms
of the amount of MMP-1 staining in any of the cell types,
Fig. 1 Immunostaining of the lungs of smokers with emphysema and
never-smoker control subjects was performed with the use of a mouse
monoclonal antibody specific to human MMP-1. Lung tissue from a
smoker with emphysema showing positive MMP-1 staining in
alveolar macrophages (a) and type II pneumocytes (b). Panel
c shows a macrophage and a type II pneumocyte negative control.
Panel d shows MMP-1-positive airway epithelial cells and panel
e shows negative airway epithelium. Arrows indicate alveolar
macrophage staining for MMP-1. Arrowheads indicate type II
pneumocyte staining for MMP-1 (20 9 for all pictures)





Sex (male/female) 2/3 13/7
Age (years) 55.2 ± 12.4 68.7 ± 11.0
Smoking history (pack years) 0 ± 0.0 52.6 ± 33.3
FEV1 % predicted 109.0 ± 16.0 79.0 ± 16.5
DLCO % predicted 89.0 ± 4.5 75.0 ± 11.3
Data are mean ± SEM
Lung (2014) 192:467–472 469
123
suggesting that smoking cessation does not result in a
decrease in MMP-1 expression. In addition, the quantita-
tive CT score did not differ significantly between the for-
mer smokers and current smokers (Table 3).
Amount of Staining and Emphysema
We analyzed whether staining in each of the cell types was
related to the surface area/volume ratio (a low ratio indi-
cates emphysema), as well as to the qualitative and quan-
titative CT grades of emphysema. Since smoking had such
a profound effect on MMP-1 expression, we limited the
analysis to the 20 subjects with a smoking history. This
addresses the question of whether smokers who develop
emphysema have increased expression of MMP-1 relative
to smokers who do not. The surface area/volume ratio was
significantly negatively related to alveolar macrophage
staining (r = -0.43, p = 0.029) but not to type II pneu-
mocyte staining (r = -0.29, p = 0.11) or airway staining
(r = -0.25, p = 0.14).
The distribution of qualitative CT emphysema scores
was grade 0 (n = 1), grade 1 (n = 9), grade 2 (n = 6), and
grade 4 (n = 1). For ease of comparison, the one subject
with grade 0 and the one subject with grade 4 were
excluded from the analysis; there were no subjects in the
grade 3 group. The amount of MMP-1 staining in alveolar
macrophages in subjects with grade 2 emphysema was
significantly greater than that of those with grade 1
emphysema (p = 0.03). There was no significant differ-
ence between the amounts of staining in type II pneumo-
cytes and airways as a function of the qualitative grade of
emphysema. There were also no significant associations
between quantitative CT values and the amount of posi-
tively stained cells. When adjusted for smoking status, the
overall emphysema score (defined using the density mask
cutoff of -855 Hounsfield units) showed a borderline
association with staining of type II pneumocytes
(p = 0.073), with higher emphysema being positively
related to staining for MMP-1.
Discussion
The results of this study provide some support for the claim
by D’Armiento et al. [7] that MMP-1, a nonelastolytic
collagenase, may play a pathogenic role in emphysema. In
addition, the results are concordant with our previous
finding of a significant relationship between MMP-1
mRNA expression by alveolar macrophages and the extent
of emphysema measured by CT scan [9]. In the present
study we demonstrated MMP-1 immunolocalization to
alveolar macrophages, type II pneumocytes, and airways.
Furthermore, MMP-1 staining was significantly increased
in smokers; in the control group there was no staining of
type II pneumocytes and only one of five individuals
showed any staining of airway epithelium. Interestingly,
the amount of MMP-1 staining did not differ between the
current and former smokers, suggesting that cigarette
smoke induces long-term changes in the expression of this
proteinase that persist after smoking cessation. Although






Alveolar macrophages 1.38a ± 0.60 9.68a ± 1.45 \0.0001
Type II pneumocytes 0.0 ± 0.0 0.78a ± 0.17 \0.0001
Airwaysb 10 ± 10 77 ± 6 0.0003
Data are mean ± SEM. The values for alveolar macrophages and
type II pneumocytes represent the volume fractions of positively
staining cells over total lung volume
a The volume fractions have been multiplied by 106 for convenience
b MMP-1 positivity of airways is expressed as the percentage of the
airways positive for MMP-1
Table 3 Staining, expressed as volume fraction and percent positive airways, and quantitative CT scores in the smoking group according to
smoking status
Former smokersa (n = 12) Current smokers (n = 8) p value
Alveolar macrophages 10.68b ± 0.195 8.19b ± 0.218 0.203
Type II pneumocytes 0.86b ± 0.25 6.62b ± 0.23 0.293
Airways 84 ± 4 67 ± 12 0.073
Overall emphysema %c 25.1 (14.3–31.7) 45.4 (32.8–49.7) 0.234
Severe emphysema %d 2.3 (0.4–13.4) 8.1 (4.9–21.3) 0.181
Data are mean ± SEM or (interquartile range)
a Study participants who quit smoking 6 months or more prior to surgery
b The volume fractions have been multiplied by 106 for convenience
c Defined using a density mask cutoff of -855 Hounsfield units
d Defined using a density mask cutoff of -910 Hounsfield units
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MMP-1 staining was increased in all smokers, there was
significantly more staining of alveolar macrophages in
individuals with a higher emphysema score. This is a novel
observation. Previously, when MMP-1 expression in the
lungs of smokers with emphysema was compared to that of
nonsmokers, substantial differences were found in MMP-1
expression by alveolar macrophages and type II pneumo-
cytes [7]. However, only two smokers without emphysema
were included in the study and thus the contribution of
smoking versus emphysema could not be distinguished.
The inflammatory mediators and proteases that initiate
and sustain proteolytic injury to the lung remain unclear.
Multiple studies have shown that the numbers of inflam-
matory cells in the lung are markedly increased in response
to cigarette smoke exposure [15]. Our findings show that
the macrophages in smokers’ lungs express increased
MMP-1 and, furthermore, that the number of positive
macrophages increases with the severity of emphysema.
However, it is not known whether this initial inflammatory
reaction is harmful or to what extent resultant upregulation
of other proteolytic enzymes also causes lung destruction.
For example, the expression of MMP-12, an elastolytic
enzyme, has also been shown to be increased in individuals
with emphysema [9]. Although transgenic upregulation of
MMP-1 in mice leads to emphysema [4], knockout of the
MMP-12 gene prevents the development of emphysema in
mice exposed to cigarette smoke [16], implicating both of
these proteases in the process. In this study we focused on
MMP-1 because of its ability to degrade type III collagen,
the major structural component of the alveolar ducts and
septa, which are key regions subjected to proteolytic
destruction in emphysema [8].
Our results are also supported by the study of Gosselink
et al. [17]. Those investigators used laser capture micro-
dissection to obtain mRNA from the alveolar region of the
peripheral lung as well as from the small airways. They
showed that MMP-1 expression was increased in the lung
parenchymal tissue as a function of increasing GOLD
COPD severity. There was no differential expression of
MMP-1 in the airways as a function of airflow obstruction.
This study has limitations. It is an observational study
examining the expression of MMP-1 within various cell
types within the lung in a small sample of subjects. We
measured the volume fraction of the lung parenchyma that
contained positive staining alveolar macrophages and type
II pneumocytes rather than the fraction of these cell types
that were positive. Therefore, it is possible that an increase
in the total number of alveolar macrophages and type II
pneumocytes in the lungs of the smokers and in the more
emphysematous subjects could contribute to the differ-
ences. Although it is true that there are more alveolar
macrophages and type II pneumocytes in the lungs of
smokers, we do not believe that this is the main source of
the difference. The alveolar macrophages and type II
pneumocytes of nonsmokers displayed little or no staining;
the signal was not due simply to increased cell number.
Similarly, there were more MMP-1-positive alveolar
macrophages and type II pneumocytes in subjects with
more severe emphysema, not simply more cells.
As discussed above, a potential weakness of this study is
that we examined the expression of only one enzyme
thought to play a destructive role in the disease process.
Furthermore, due to our limited sample size, we were not
able to fully examine the relationship between MMP-1
expression and all of the GOLD stages of disease or grades
of emphysema. Our never-smoker controls were younger
than our smokers, with and without emphysema, primarily
due to the difficulty of obtaining normal samples from
patients in their fifth and sixth decade of life, when
emphysema normally affects patients.
In summary, our findings further support the proposal that
inflammatory cells (alveolar macrophages), as well as type II
pneumocytes and airway epithelium, are a significant source
of MMP-1 and that this enzyme plays a role in the patho-
genesis of emphysema, even after smoking cessation. In
addition, increased MMP-1 expression correlates with more
severe disease, suggesting that MMP-1 plays a role in the
disease process and that regulation of this enzyme may prove
to be a valuable therapeutic intervention.
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